116 related articles for article (PubMed ID: 31409078)
21. [Relationship of clinicopathological features and chemotherapeutic outcomes in women with BRCA1 and BRCA2 mutation-negative familial breast cancer].
Zhang J; Sun J; Ouyang T; Li JF; Wang TF; Fan ZQ; Fan T; Lin BY; Xie YT
Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):185-9. PubMed ID: 26988823
[TBL] [Abstract][Full Text] [Related]
22. The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients.
Huszno J; Budryk M; Kołosza Z; Nowara E
Oncology; 2013; 85(5):278-82. PubMed ID: 24217135
[TBL] [Abstract][Full Text] [Related]
23. BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM; Garber JE
Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
[TBL] [Abstract][Full Text] [Related]
24. Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines.
Barac A; Lynce F; Smith KL; Mete M; Shara NM; Asch FM; Nardacci MP; Wray L; Herbolsheimer P; Nunes RA; Swain SM; Warren R; Peshkin BN; Isaacs C
Breast Cancer Res Treat; 2016 Jan; 155(2):285-93. PubMed ID: 26749359
[TBL] [Abstract][Full Text] [Related]
25. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
Maxwell KN; Wubbenhorst B; Wenz BM; De Sloover D; Pluta J; Emery L; Barrett A; Kraya AA; Anastopoulos IN; Yu S; Jiang Y; Chen H; Zhang NR; Hackman N; D'Andrea K; Daber R; Morrissette JJD; Mitra N; Feldman M; Domchek SM; Nathanson KL
Nat Commun; 2017 Aug; 8(1):319. PubMed ID: 28831036
[TBL] [Abstract][Full Text] [Related]
26. [Breast cancer in BRCA1/2 mutation carriers].
Fabian P; Nenutil R
Cesk Patol; 2016; 52(4):206-209. PubMed ID: 27869445
[TBL] [Abstract][Full Text] [Related]
27. PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers.
Stebbing J; Ellis P; Tutt A
Future Oncol; 2010 Apr; 6(4):485-6. PubMed ID: 20373860
[No Abstract] [Full Text] [Related]
28. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
Isakoff SJ; Puhalla S; Domchek SM; Friedlander M; Kaufman B; Robson M; Telli ML; Diéras V; Han HS; Garber JE; Johnson EF; Maag D; Qin Q; Giranda VL; Shepherd SP
Future Oncol; 2017 Feb; 13(4):307-320. PubMed ID: 27739325
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
Zayas-Villanueva OA; Campos-Acevedo LD; Lugo-Trampe JJ; Hernández-Barajas D; González-Guerrero JF; Noriega-Iriondo MF; Ramírez-Sánchez IA; Martínez-de-Villarreal LE
BMC Cancer; 2019 Jul; 19(1):722. PubMed ID: 31331294
[TBL] [Abstract][Full Text] [Related]
30. Contribution of Massive Parallel Sequencing to Diagnosis of Hereditary Ovarian Cancer in the Czech Republic.
Soukupová J; Lhotová K; Zemánková P; Vočka M; Janatová M; Stolařová L; Borecká M; Kleiblová P; Macháčková E; Foretová L; Koudová M; Lhota F; Tavandzis S; Zikán M; Stránecký V; Veselá K; Panczak A; Kotlas J; Kleibl Z
Klin Onkol; 2019; 32(Supplementum2):72-78. PubMed ID: 31409082
[TBL] [Abstract][Full Text] [Related]
31. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
[TBL] [Abstract][Full Text] [Related]
32. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
33. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
[TBL] [Abstract][Full Text] [Related]
34. Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival.
Alvarez C; Aravena A; Tapia T; Rozenblum E; Solís L; Corvalán A; Camus M; Alvarez M; Munroe D; Maass A; Carvallo P
BMC Cancer; 2016 Mar; 16():219. PubMed ID: 26979459
[TBL] [Abstract][Full Text] [Related]
35. In brief: BRCA1 and BRCA2.
Foulkes WD; Shuen AY
J Pathol; 2013 Aug; 230(4):347-9. PubMed ID: 23620175
[TBL] [Abstract][Full Text] [Related]
36. Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors.
Arnold JM; Choong DY; Thompson ER; ; Waddell N; Lindeman GJ; Visvader JE; Campbell IG; Chenevix-Trench G
Breast Cancer Res Treat; 2010 Jan; 119(2):491-6. PubMed ID: 19189213
[TBL] [Abstract][Full Text] [Related]
37. Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes.
Tsyganov MM; Ibragimova MK; Garbukov EY; Bragina OD; Karchevskaya AA; Usynin EA; Litvyakov NV
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613648
[TBL] [Abstract][Full Text] [Related]
38. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
[TBL] [Abstract][Full Text] [Related]
39.
Lips EH; Debipersad RD; Scheerman CE; Mulder L; Sonke GS; van der Kolk LE; Wesseling J; Hogervorst FB; Nederlof PM
Clin Cancer Res; 2017 Mar; 23(5):1236-1241. PubMed ID: 27620280
[No Abstract] [Full Text] [Related]
40. Evolving treatment strategies for triple-negative breast cancer.
Telli M
J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):652-4. PubMed ID: 25995421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
